基本信息
views: 244
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
I am a physician-scientist who has established a human translational research group that fosters the development of both laboratory immunologists, and clinical translational researchers. Allogeneic hematopoietic cell transplantation (alloHCT) cures blood cancer via beneficial graft-v-tumor immunity. Our overall research goal is to augment GVT while preventing dertimental graft versus host disease (GVHD). The Miklos lab pioneered protein microarray technologies to disciiver clinically relevant allogeneic antibodies, especially those targeting H-Y antigens following sex mismatched transplantation. Our discovery that allogeneic HY antibodies develop in association with chronic GVHD revealed a critical B cell role in chronic GVHD pathogenesis and our clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. We developed high-throughput sequencing of the B and T cell immune receptor thereby enabling: 1) lymphoid disease quantification, 2) detailed B and T cell donor reconstitution kinetics, and 3) clonal analysis of antigen specific responses following allo-HCT.
Immunotherapy is revolutionizing cancer treatment and as the Stanford Clinical Cancer Cell Therapy program develops and evaluates the most promising cutting-edge cell therapies for cancer patients on a variety of clinical trials. Chimeric Antigen T Cell (CAR-T) therapy targets the patient's T lymphocytes to attack their cancer by infecting their own T cells to express chimeric antigen receptor (CAR) proteins that target and kill cancer cell expressing surface proteins. Thus far, the most successful CAR-T have targeted B cell antigen CD19, and ongoing trials are treating patients with relapsed/refractory Diffuse Large B Cell Lymphoma (DLBCL) using this CAR19 therapy.
Immunotherapy is revolutionizing cancer treatment and as the Stanford Clinical Cancer Cell Therapy program develops and evaluates the most promising cutting-edge cell therapies for cancer patients on a variety of clinical trials. Chimeric Antigen T Cell (CAR-T) therapy targets the patient's T lymphocytes to attack their cancer by infecting their own T cells to express chimeric antigen receptor (CAR) proteins that target and kill cancer cell expressing surface proteins. Thus far, the most successful CAR-T have targeted B cell antigen CD19, and ongoing trials are treating patients with relapsed/refractory Diffuse Large B Cell Lymphoma (DLBCL) using this CAR19 therapy.
Research Interests
Papers共 453 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Mark P. Hamilton,Takeshi Sugio,Troy Noordenbos, Shuyu Shi,Philip L. Bulterys,Chih Long Liu,Xiaoman Kang, Mari N. Olsen,Zinaida Good,Saurabh Dahiya,Matthew J. Frank,Bita Sahaf,
NEW ENGLAND JOURNAL OF MEDICINEno. 22 (2024): 2047-2060
Journal for ImmunoTherapy of Cancerno. 7 (2024)
Jay Spiegel,Jean S. Oak,Anmol Goyal, Scott Bornheimer, Allison Irvine,Rhine R. Shen,Katherine A. Kong,Sushma Bharadwaj,Wen-Kai Weng,Melody Smith,Matthew J. Frank,Saurabh Dahiya,
Transplantation and Cellular Therapyno. 2 (2024): S204
crossref(2024)
American Journal of Hematologyno. 5 (2024): 880-889
Sushma Bharadwaj,Eric Lau,Mark P Hamilton,Anmol Goyal, Hrishi Srinagesh,Alexandria Jensen,Dasom Lee,Jayasindhu Mallampet, Sarah Elkordy,Shriya Syal,Sunita Patil,Theresa Latchford,
TRANSPLANTATION AND CELLULAR THERAPYno. 5 (2024): 518e1-518e13
Transplantation and Cellular Therapyno. 2 (2024): S487-S488
Load More
Author Statistics
#Papers: 459
#Citation: 18145
H-Index: 52
G-Index: 132
Sociability: 8
Diversity: 2
Activity: 122
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn